BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Caerus Discovery, LLC, New Biotechnology Company is Announced


6/1/2011 11:39:59 AM

Caerus Discovery was launched today to develop a novel platform for rapid discovery and development of therapeutic targets and biomarkers. Caerus was initiated with program support from BioWa, Inc and certain antibody technologies from Immunocellular Therapeutics, Ltd (OTCBB: IMUC).

“We are very excited to employ our proprietary platform technology to discover novel disease biomarkers for diagnostic and therapeutic applications, and are fortunate to be starting this venture with two very experienced partners”

Caerus uses combinations of proprietary adjuvants, high zone tolerance and subtractive immunization to identify differentially expressed targets, which may be exceedingly rare, cryptic or unavailable to other techniques due to their chemical composition.

In return for the technology rights transferred, ICT received equity in the new company. BioWa received certain rights to future technologies developed by Caerus. Other aspects of the financial arrangements of the formation were not disclosed.

“We are very excited to employ our proprietary platform technology to discover novel disease biomarkers for diagnostic and therapeutic applications, and are fortunate to be starting this venture with two very experienced partners” said Cohava Gelber, PhD, MBA, President & CEO of Caerus Discovery, LLC.

According to Yasunori Yamaguchi, Ph.D., the President and CEO of BioWa, “Caerus brings a very promising approach to the discovery of druggable disease targets. We are excited about the prospects of our partnership”.

Dr. Manish Singh, President and CEO of Immunocellular said that “I am pleased that the technology assets in our monoclonal antibody discovery area will now have a stronger opportunity to build value for our shareholders”.

About Caerus Discovery LLC

Caerus Discovery LLC is a privately owned company based on the Prince William Campus of George Mason University in Manassas, VA. Caerus is focused on the discovery of new molecular targets for cancer, autoimmune, inflammatory and infectious diseases. Caerus plans to further develop and optimize novel discovery paradigms employing immune tolerance induction prior to immunization to unravel new targets and molecules for diagnostic and therapeutic applications.

About BioWa

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of the AccretaMab® platform. The AccretaMab® platform consists of POTELLIGENT® and COMPLEGENT® Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT® and COMPLEGENT® Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at www.biowa.com. POTELLIGENT®, COMPLEGENT®, and AccretaMab® are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMUC, please visit www.imuc.com.

Caerus Inquiries: President and CEO: Cohava Gelber Ph.D., MBA +1-703 343 3258

Cohava@caerusdiecovery.com BioWa Inquiries: President and CEO: Yasunori Yamaguchi, Ph.D. +1-609-580-7500 Contacts

ImmunoCellular Therapeutics, Ltd. CEOcast, Inc. James Young, 212-732-4300 Investor Relations jyoung@ceocast.com

Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES